Coronavirus vaccine stocks may not be the hottest stocks in the stock market today. However, the companies behind them continue to play crucial roles in the fight against Covid-19 now. By and large, this is the case as new variants continue to emerge that are boasting greater infectivity. Despite all of this, coronavirus stocks have mostly cooled off since their…
At the beginning of the year, the two biotechs highlighted in today’s article weren’t even big enough to be considered microcap stocks. Now, thanks to their respective COVID-19 vaccine programs, both are fast-growing small-cap stocks with “intriguing twists with their respective COVID-19 vaccine candidates.” So which of these two coronavirus stocks might be the better buy? CLICK HERE.
When it comes to the advantage that emerging coronavirus stocks have over their more established counterparts, the author of today’s article notes that, “While coronavirus vaccine companies such as Moderna, AstraZeneca, and Pfizer have market caps amounting to tens of billions of dollars, small- to mid-cap coronavirus stocks can potentially be multi-baggers, albeit with higher risks.” He proceeds to take…